Amneal Pharmaceuticals, Inc. AMRX

Company Overview

Amneal Pharmaceuticals, Inc. is a U.S.-based pharmaceutical company that develops, manufactures, markets, and distributes generic medicines, specialty pharmaceuticals, biosimilars, and active pharmaceutical ingredients (APIs). The company operates primarily in the healthcare and pharmaceutical manufacturing industries, with a business model centered on supplying lower-cost generic medications alongside branded specialty treatments targeting central nervous system and endocrine disorders. Its core revenue drivers include its broad portfolio of generic prescription products sold in the United States, specialty branded products, and pharmaceutical ingredient manufacturing through its API operations.

The company traces its origins to 2002, when brothers Chirag Patel and Chintu Patel founded Amneal Pharmaceuticals. Amneal expanded through organic growth and acquisitions, including the combination with Impax Laboratories in 2018, which materially increased its scale in generics and specialty pharmaceuticals. The company has positioned itself as a vertically integrated pharmaceutical manufacturer with capabilities spanning development, manufacturing, distribution, and API production. Its strategy emphasizes operational scale, complex generics, injectables, biosimilars, and specialty branded therapeutics in high-demand therapeutic areas.